|
1
|
Mangaonkar AA and Patnaik MM: Patterns of
care and survival for elderly acute myeloid leukemia-challenges and
opportunities. Curr Hematol Malig Rep. 12:290–299. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DiNardo CD, Pratz KW, Letai A, Jonas BA,
Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic
R, et al: Safety and preliminary efficacy of venetoclax with
decitabine or azacitidine in elderly patients with previously
untreated acute myeloid leukaemia: A non-randomised, open-label,
phase 1b study. Lancet Oncol. 19:216–228. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DiNardo CD, Pratz K, Pullarkat V, Jonas
BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH,
Kantarjian HM, et al: Venetoclax combined with decitabine or
azacitidine in treatment-naive, elderly patients with acute myeloid
leukemia. Blood. 133:7–17. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
DiNardo CD, Jonas BA, Pullarkat V, Thirman
MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, et
al: Azacitidine and venetoclax in previously untreated acute
myeloid leukemia. N Engl J Med. 383:617–629. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Winters AC, Gutman JA, Purev E, Nakic M,
Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, et al:
Real-world experience of venetoclax with azacitidine for untreated
patients with acute myeloid leukemia. Blood Adv. 3:2911–2919. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Morsia E, McCullough K, Joshi M, Cook J,
Alkhateeb HB, Al-Kali A, Begna K, Elliott M, Hogan W, Litzow M, et
al: Venetoclax and hypomethylating agents in acute myeloid
leukemia: Mayo clinic series on 86 patients. Am J Hematol.
95:1511–1521. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lou D, Liu L and Qin WW: Clinical analysis
of venetoclax combined with azacitidine in elderly patients with
newly diagnosed acute myeloid leukemia. Chin J Clin Oncol.
49:775–780. 2022.(In Chinese).
|
|
8
|
Zhang B, Ji JM, Wu Y, Ji O, Lin L and Zhu
G: Clinical efficacy and safety analysis of azacytidine combined
with venetoclax in patients with newly diagnosed acute myeloid
leukemia who cannot tolerate conventional chemotherapy. J Clin
Intern Med. 39:632–634. 2022.(In Chinese).
|
|
9
|
Vachhani P, Flahavan EM, Xu T, Ma E,
Montez M, Gershon A, Onishi M, Jin H, Ku G, Flores B, et al:
Venetoclax and hypomethylating agents as first-line treatment in
newly diagnosed patients with AML in a predominately community
setting in the US. Oncologist. 27:907–918. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pollyea DA, Bixby D, Perl A, Bhatt VR,
Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, et
al: NCCN guidelines insights: Acute myeloid leukemia, version
2.2021. J Natl Compr Canc Netw. 19:16–27. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Young J, Badgery-Parker T, Dobbins T,
Jorgensen M, Gibbs P, Faragher I, Jones I and Currow D: Comparison
of ECOG/WHO performance status and ASA score as a measure of
functional status. J Pain Symptom Manage. 49:258–264. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: Using the common terminology criteria
for adverse events (CTCAE-version 5.0) to evaluate the severity of
adverse events of anticancer therapies. Actas Dermosifiliogr (Engl
Ed). 112:90–92. 2021.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dhopeshwarkar N, Iqbal S, Wang X and Salas
M: A retrospective study of comorbidities and complications in
elderly acute myeloid leukemia patients in the United States. Clin
Lymphoma Myeloma Leuk. 19:e436–e456. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Oran B and Weisdorf DJ: Survival for older
patients with acute myeloid leukemia: A population-based study.
Haematologica. 97:1916–1924. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Döhner H, Lübbert M, Fiedler W, Fouillard
L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann
OG, et al: Randomized, phase 2 trial of low-dose cytarabine with or
without volasertib in AML patients not suitable for induction
therapy. Blood. 124:1426–1433. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dombret H, Seymour JF, Butrym A,
Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC,
Candoni A, et al: International phase 3 study of azacitidine vs
conventional care regimens in older patients with newly diagnosed
AML with >30% blasts. Blood. 126:291–299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Al-Ali HK, Jaekel N, Junghanss C,
Maschmeyer G, Krahl R, Cross M, Hoppe G and Niederwieser D:
Azacitidine in patients with acute myeloid leukemia medically unfit
for or resistant to chemotherapy: A multicenter phase I/II study.
Leuk Lymphoma. 53:110–117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He PF, Zhou JD, Yao DM, Ma JC, Wen XM,
Zhang ZH, Lian XY, Xu ZJ, Qian J and Lin J: Efficacy and safety of
decitabine in treatment of elderly patients with acute myeloid
leukemia: A systematic review and meta-analysis. Oncotarget.
8:41498–41507. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hong M, Zhu H, Sun Q, Zhu Y, Miao Y, Yang
H, Qiu HR, Li JY and Qian SX: Decitabine in combination with
low-dose cytarabine, aclarubicin and G-CSF tends to improve
prognosis in elderly patients with high-risk AML. Aging (Albany
NY). 12:5792–5811. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang J, Hong M, Zhu Y, Zhao H, Zhang X,
Wu Y, Lian Y, Zhao X, Li J and Qian S: Decitabine in combination
with G-CSF, low-dose cytarabine and aclarubicin is as effective as
standard dose chemotherapy in the induction treatment for patients
aged from 55 to 69 years old with newly diagnosed acute myeloid
leukemia. Leuk Lymphoma. 59:2570–2579. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie M, Jiang Q, Li L, Zhu J, Zhu L, Zhou
D, Zheng Y, Yang X, Zhu M, Sun J, et al: HAG (homoharringtonine,
cytarabine, G-CSF) regimen for the treatment of acute myeloid
leukemia and myelodysplastic syndrome: A meta-analysis with 2,314
participants. PLoS One. 11:e01642382016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suzushima H, Wada N, Yamasaki H, Eto K,
Shimomura T, Kugimiya MH, Horikawa K, Nishimura S, Tsuda H, Mitsuya
H and Asou N: Low-dose cytarabine and aclarubicin in combination
with granulocyte colony-stimulating factor for elderly patients
with previously untreated acute myeloid leukemia. Leuk Res.
34:610–614. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hackl H, Astanina K and Wieser R:
Molecular and genetic alterations associated with therapy
resistance and relapse of acute myeloid leukemia. J Hematol Oncol.
10:512017. View Article : Google Scholar : PubMed/NCBI
|
